208 related articles for article (PubMed ID: 36859300)
1. Denosumab-induced hypocalcemia post bariatric surgery-a severe and protracted course: a case report.
Awang MH; Hatta SFWM; Mohamad AF; Ghani RA
J Med Case Rep; 2023 Mar; 17(1):73. PubMed ID: 36859300
[TBL] [Abstract][Full Text] [Related]
2. Denosumab-Induced Hypocalcemia after Billroth II Gastric Bypass Surgery.
Schmucker AM; Green DE; Montemuro PM
Case Rep Endocrinol; 2020; 2020():8833723. PubMed ID: 32774945
[TBL] [Abstract][Full Text] [Related]
3. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
4. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
5. Previous gastric bypass surgery complicating total thyroidectomy.
Alfonso B; Jacobson AS; Alon EE; Via MA
Ear Nose Throat J; 2015 Mar; 94(3):E12-6. PubMed ID: 25738720
[TBL] [Abstract][Full Text] [Related]
6. Hypocalcemia in Patients With Osteoporosis and Normal Renal Function, Treated With Denosumab, a Retrospective Analysis.
Bitar ZI; Hajjiah AM; Maadarani OS; Elzoueiry MM; Gohar MR; Abdelfatah M; Alabdali F
Nutr Metab Insights; 2024; 17():11786388231223604. PubMed ID: 38205220
[TBL] [Abstract][Full Text] [Related]
7. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
8. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
9. SEVERE, PROLONGED, DENOSUMAB-INDUCED HYPOCALCEMIA WITH RECOVERY AFTER 111 DAYS OF HIGH-DOSE CALCIUM SUPPLEMENTATION.
McCaleb RV; Johnson JT
AACE Clin Case Rep; 2019; 5(1):e82-e85. PubMed ID: 31967007
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D
Ikegami K; Hashiguchi M; Kizaki H; Yasumuro O; Funakoshi R; Hori S
J Clin Pharmacol; 2022 Sep; 62(9):1151-1159. PubMed ID: 35383950
[TBL] [Abstract][Full Text] [Related]
12. Calcifediol Rather Than Cholecalciferol for a Patient Submitted to Malabsortive Bariatric Surgery: A Case Report.
Brancatella A; Cappellani D; Vignali E; Canale D; Marcocci C
J Endocr Soc; 2017 Aug; 1(8):1079-1084. PubMed ID: 29264560
[TBL] [Abstract][Full Text] [Related]
13. [Symptomatic hypocalcaemia on denosumab use].
Baptista Lopes V; Robbrecht D; van Thiel S; van Guldener C
Ned Tijdschr Geneeskd; 2013; 157(29):A6159. PubMed ID: 23859106
[TBL] [Abstract][Full Text] [Related]
14. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
15. Hypocalcaemia following denosumab in prostate cancer: A clinical review.
Lau LH; Cliff ERS; Wong V; Wong H; Torkamani N; Eer A; Weickhardt A; Grossmann M
Clin Endocrinol (Oxf); 2020 Jun; 92(6):495-502. PubMed ID: 32017154
[TBL] [Abstract][Full Text] [Related]
16. Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients.
Cianciolo G; Tondolo F; Barbuto S; Iacovella F; Zavatta G; Altieri P; Grandinetti V; Comai G; Cozzolino M; La Manna G
Am J Nephrol; 2021; 52(8):611-619. PubMed ID: 34518468
[TBL] [Abstract][Full Text] [Related]
17. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study.
Cowan A; Jeyakumar N; McArthur E; Fleet JL; Kanagalingam T; Karp I; Khan T; Muanda FT; Nash DM; Silver SA; Thain J; Weir MA; Garg AX; Clemens KK
J Bone Miner Res; 2023 May; 38(5):650-658. PubMed ID: 36970786
[TBL] [Abstract][Full Text] [Related]
18. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
19. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
20. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
